Skip to content

Enliven Therapeutics, Inc.

ELVN

CIK 0001672619

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$97.65M
−16.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.76
+3.2% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$87.69M
Q1 Apr 2026
Cash
$132.18M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
60.9M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings